MeiraGTx Holdings plc Increase (Decrease) in Accrued Liabilities
MeiraGTx Holdings plc (MGTX) reported Increase (Decrease) in Accrued Liabilities of -$12.84 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-13
- MeiraGTx Holdings plc increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was -$2.94M.
- MeiraGTx Holdings plc increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was -$9.90M.
- MeiraGTx Holdings plc increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was $8.74M, a 6.95% decline year-over-year.
- MeiraGTx Holdings plc increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was $8.27M, a 423.83% increase year-over-year.
- MeiraGTx Holdings plc increase (decrease) in accrued liabilities for fiscal 2025 was $4.41M.
- MeiraGTx Holdings plc increase (decrease) in accrued liabilities for fiscal 2024 was -$13.96M.
- MeiraGTx Holdings plc increase (decrease) in accrued liabilities for fiscal 2023 was -$382.00K, a 103.03% decline from fiscal 2022.
- MeiraGTx Holdings plc increase (decrease) in accrued liabilities for fiscal 2022 was $12.61M, a 55.33% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 3 month as first filed | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 6 month as first filed | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 9 month as first filed | Increase (Decrease) in Accrued Liabilities 12 month | Increase (Decrease) in Accrued Liabilities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$2.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$12.84M 10-Q · filed 2026-08-13 | -$4.10M derived: sum of 3 quarters · filed 2026-08-13 | $4.16M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | -$9.90M 10-Q · filed 2026-05-14 | -$1.17M derived: sum of 2 quarters · filed 2026-05-14 | $7.10M derived: sum of 3 quarters · filed 2026-05-14 | -$1.91M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | $8.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $17.00M derived: sum of 2 quarters · filed 2026-03-30 | $7.99M derived: sum of 3 quarters · filed 2026-08-13 | $4.41M 10-K · filed 2026-03-30 | ||||
| 2025-09-30 | $8.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$744.00K derived: sum of 2 quarters · filed 2026-08-13 | -$4.33M 10-Q · filed 2025-11-13 | $5.06M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | -$9.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$12.60M 10-Q · filed 2026-08-13 | -$3.20M derived: sum of 3 quarters · filed 2026-08-13 | -$1.63M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | -$3.58M 10-Q · filed 2026-05-14 | $5.81M derived: sum of 2 quarters · filed 2026-05-14 | $7.38M derived: sum of 3 quarters · filed 2026-05-14 | $6.69M derived: sum of 4 quarters · filed 2026-05-14 | ||||
| 2024-12-31 | $9.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $10.97M derived: sum of 2 quarters · filed 2026-03-30 | $10.27M derived: sum of 3 quarters · filed 2026-03-30 | -$13.96M 10-K · filed 2026-03-30 | ||||
| 2024-09-30 | $1.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $881.00K derived: sum of 2 quarters · filed 2025-11-13 | -$23.35M 10-Q · filed 2025-11-13 | -$9.81M derived: sum of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | -$697.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$24.93M 10-Q · filed 2025-08-14 | -$11.39M derived: sum of 3 quarters · filed 2025-08-14 | -$8.08M derived: sum of 4 quarters · filed 2025-08-14 | ||||
| 2024-03-31 | -$24.23M 10-Q · filed 2025-05-13 | -$10.70M derived: sum of 2 quarters · filed 2025-05-13 | -$7.38M derived: sum of 3 quarters · filed 2025-05-13 | -$13.14M derived: sum of 4 quarters · filed 2025-05-13 | ||||
| 2023-12-31 | $13.54M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $16.85M derived: sum of 2 quarters · filed 2025-03-13 | $11.09M derived: sum of 3 quarters · filed 2025-03-13 | -$382.00K 10-K · filed 2025-03-13 | ||||
| 2023-09-30 | $3.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$2.45M derived: sum of 2 quarters · filed 2024-11-13 | -$13.92M 10-Q · filed 2024-11-13 | -$2.25M derived: sum of 4 quarters · filed 2024-11-13 | ||||
| 2023-06-30 | -$5.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$17.23M 10-Q · filed 2024-08-12 | -$5.57M derived: sum of 3 quarters · filed 2024-08-12 | -$3.57M derived: sum of 4 quarters · filed 2024-08-12 | ||||
| 2023-03-31 | -$11.47M 10-Q · filed 2024-05-09 | $197.00K derived: sum of 2 quarters · filed 2024-05-09 | $2.20M derived: sum of 3 quarters · filed 2024-05-09 | $4.97M derived: sum of 4 quarters · filed 2024-05-09 | ||||
| 2022-12-31 | $11.67M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $13.67M derived: sum of 2 quarters · filed 2024-03-15 | $16.44M derived: sum of 3 quarters · filed 2024-03-15 | $12.61M 10-K · filed 2024-03-15 | ||||
| 2022-09-30 | $2.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $4.78M derived: sum of 2 quarters · filed 2023-11-14 | $944.00K 10-Q · filed 2023-11-14 | $11.07M derived: sum of 4 quarters · filed 2023-11-14 | ||||
| 2022-06-30 | $2.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$1.06M 10-Q · filed 2023-08-10 | $9.07M derived: sum of 3 quarters · filed 2023-08-10 | $12.11M derived: sum of 4 quarters · filed 2023-08-10 | ||||
| 2022-03-31 | -$3.83M 10-Q · filed 2023-05-11 | $6.30M derived: sum of 2 quarters · filed 2023-05-11 | $9.34M derived: sum of 3 quarters · filed 2023-05-11 | $9.36M derived: sum of 4 quarters · filed 2023-05-11 | ||||
| 2021-12-31 | $10.13M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $13.17M derived: sum of 2 quarters · filed 2023-03-14 | $13.19M derived: sum of 3 quarters · filed 2023-03-14 | $8.12M 10-K · filed 2023-03-14 | ||||
| 2021-09-30 | $3.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $3.06M derived: sum of 2 quarters · filed 2022-11-10 | -$2.01M 10-Q · filed 2022-11-10 | $2.79M derived: sum of 4 quarters · filed 2022-11-10 | ||||
| 2021-06-30 | $23.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$5.05M 10-Q · filed 2022-08-11 | -$243.00K derived: sum of 3 quarters · filed 2022-08-11 | -$4.03M derived: sum of 4 quarters · filed 2022-08-11 | ||||
| 2021-03-31 | -$5.07M 10-Q · filed 2022-05-12 | -$266.00K derived: sum of 2 quarters · filed 2022-05-12 | -$4.05M derived: sum of 3 quarters · filed 2022-05-12 | $1.58M derived: sum of 4 quarters · filed 2022-05-12 | ||||
| 2020-12-31 | $4.80M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $1.02M derived: sum of 2 quarters · filed 2022-03-10 | $6.65M derived: sum of 3 quarters · filed 2022-03-10 | $2.17M 10-K · filed 2022-03-10 | $2.17M 10-K · filed 2021-03-11 | |||
| 2020-09-30 | -$3.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $1.84M derived: sum of 2 quarters · filed 2021-11-10 | -$2.63M 10-Q · filed 2021-11-10 | -$2.63M 10-Q · filed 2020-11-05 | $6.31M derived: sum of 4 quarters · filed 2021-11-10 | |||
| 2020-06-30 | $5.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $1.15M 10-Q · filed 2021-08-11 | $1.15M 10-Q · filed 2020-08-06 | $10.10M derived: sum of 3 quarters · filed 2021-08-11 | $10.03M derived: sum of 4 quarters · filed 2021-08-11 | |||
| 2020-03-31 | -$4.48M 10-Q · filed 2021-05-11 | -$4.48M 10-Q · filed 2020-05-07 | $4.47M derived: sum of 2 quarters · filed 2021-05-11 | $4.40M derived: sum of 3 quarters · filed 2021-05-11 | $6.16M derived: sum of 4 quarters · filed 2021-05-11 | |||
| 2019-12-31 | $8.95M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $8.87M derived: sum of 2 quarters · filed 2021-03-11 | $10.64M derived: sum of 3 quarters · filed 2021-03-11 | $6.52M 10-K · filed 2021-03-11 | ||||
| 2019-09-30 | -$72.62K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $1.70M derived: sum of 2 quarters · filed 2020-11-05 | -$2.43M 10-Q · filed 2020-11-05 | $3.60M derived: sum of 4 quarters · filed 2020-11-05 | ||||
| 2019-06-30 | $1.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$2.36M 10-Q · filed 2020-08-06 | $3.67M derived: sum of 3 quarters · filed 2020-08-06 | $4.92M derived: sum of 4 quarters · filed 2020-08-06 | ||||
| 2019-03-31 | -$4.12M 10-Q · filed 2020-05-07 | $1.90M derived: sum of 2 quarters · filed 2020-05-07 | $3.15M derived: sum of 3 quarters · filed 2020-05-07 | $1.25M derived: sum of 4 quarters · filed 2020-05-07 | ||||
| 2018-12-31 | $6.03M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11 | $7.28M derived: sum of 2 quarters · filed 2020-03-11 | $5.38M derived: sum of 3 quarters · filed 2020-03-11 | $2.53M 10-K · filed 2020-03-11 | ||||
| 2018-09-30 | $1.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | -$650.59K derived: sum of 2 quarters · filed 2019-11-07 | -$3.50M 10-Q · filed 2019-11-07 | -$994.35K derived: sum of 4 quarters · filed 2019-11-07 | ||||
| 2018-06-30 | -$1.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | -$4.75M 10-Q · filed 2019-08-07 | -$2.25M derived: sum of 3 quarters · filed 2019-08-07 | -$131.69K derived: sum of 4 quarters · filed 2019-08-07 | ||||
| 2018-03-31 | -$2.85M 10-Q · filed 2019-05-14 | -$343.76K derived: sum of 2 quarters · filed 2019-05-14 | $1.77M derived: sum of 3 quarters · filed 2019-05-14 | |||||
| 2017-12-31 | $2.50M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-26 | $4.62M derived: sum of 2 quarters · filed 2019-03-26 | $4.97M 10-K · filed 2019-03-26 | |||||
| 2017-09-30 | $2.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $2.47M 10-Q · filed 2018-11-08 | ||||||
| 2017-06-30 | $352.54K 10-Q · filed 2018-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |